Ye Yang

List of Publications by Year in Descending Order

85 papers	1,306 citations	18 h-index	33 g-index
93 ext. papers	1,813 ext. citations	6.7 avg, IF	4.68 L-index

#	Paper	IF	Citations
85	Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer.. *Pharmacology & Therapeutics*, **2022**, 234, 108123	13.9	3
84	AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 11	12.8	2
83	Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication.. *Clinical and Translational Medicine*, **2022**, 12, e684	5.7	1
82	A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 85	12.8	0
81	The role of Wnt/β-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review). *American Journal of Translational Research (discontinued)*, **2021**, 13, 9932-9949	3	
80	BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability. *Signal Transduction and Targeted Therapy*, **2021**, 6, 361	21	5
79	Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice Decreasing Metabolic Ornithine. *Frontiers in Oncology*, **2021**, 11, 779562	5.3	0
78	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. *Journal of Hematology and Oncology*, **2021**, 14, 54	22.4	17
77	Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib. *Cell Death and Disease*, **2021**, 12, 429	9.8	2
76	Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 675939	5.7	3
75	CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients. *Journal of Hematology and Oncology*, **2021**, 14, 90	22.4	3
74	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. *Molecular Cancer*, **2021**, 20, 84	42.1	9
73	MK2 is a therapeutic target for high-risk multiple myeloma. *Haematologica*, **2021**, 106, 1774-1777	6.6	5
72	RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. *Leukemia*, **2021**, 35, 1803-1807	10.7	5
71	Review on circular RNAs and new insights into their roles in cancer. *Computational and Structural Biotechnology Journal*, **2021**, 19, 910-928	6.8	43
70	Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. *Cell Death and Disease*, **2021**, 12, 206	9.8	5
69	Alternative splicing and cancer: a systematic review. *Signal Transduction and Targeted Therapy*, **2021**, 6, 78	21	34

68	Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway. *BMC Complementary Medicine and Therapies*, **2020**, 20, 179	2.9	6
67	Effect of Decoction on Movement Disorder and Substantia Nigra Dopaminergic Neurons in Mice with Chronic Parkinson's Disease. *Evidence-based Complementary and Alternative Medicine*, **2020**, 2020, 9838295	2.3	2
66	Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma. *Frontiers in Oncology*, **2020**, 10, 767	5.3	12
65	Research Advances on Acupuncture Analgesia. *The American Journal of Chinese Medicine*, **2020**, 48, 245-258	3.8	17
64	Bioactive Compounds from . Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment. *OncoTargets and Therapy*, **2020**, 13, 959-973	4.4	8
63	CHEK1 and circCHEK1_246aa Promote Multiple Myeloma Malignancy By Evoking Chromosomal Instability and Bone Lesion. *Blood*, **2020**, 136, 9-10	2.2	
62	In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma. *Aging*, **2020**, 12, 22949-22974	5.6	1
61	Lobetyolin induces apoptosis of colon cancer cells by inhibiting glutamine metabolism. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 3359-3369	5.6	17
60	CASC21, a FOXP1 induced long non-coding RNA, promotes colorectal cancer growth by regulating CDK6. *Aging*, **2020**, 12, 12086-12106	5.6	7
59	and efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma. *Aging*, **2020**, 12, 22949-22974	5.6	1
58	Exploring the role of glucose-6-phosphate dehydrogenase in cancer (Review). *Oncology Reports*, **2020**, 44, 2325-2336	3.5	5
57	Integration of organ metabolomics and proteomics in exploring the blood enriching mechanism of Danggui Buxue Decoction in hemorrhagic anemia rats. *Journal of Ethnopharmacology*, **2020**, 261, 113000	5	4
56	Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK/mTOR signaling. *Signal Transduction and Targeted Therapy*, **2020**, 5, 174	21	16
55	Steroid 5-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-B/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer. *Frontiers in Oncology*, **2020**, 10, 1501	5.3	2
54	Low molecular weight heparin (nadroparin) improves placental permeability in rats with gestational diabetes mellitus via reduction of tight junction factors. *Molecular Medicine Reports*, **2020**, 21, 623-630	2.9	4
53	Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. *Journal of the National Cancer Institute*, **2020**, 112, 507-515	9.7	13
52	Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma. *Frontiers in Oncology*, **2019**, 9, 722	5.3	3
51	Lycium barbarum polysaccharides attenuate rat anti-Thy-1 glomerulonephritis through mediating pyruvate dehydrogenase. *Biomedicine and Pharmacotherapy*, **2019**, 116, 109020	7.5	6

50	Germline Risk Contribution to Genomic Instability in Multiple Myeloma. *Frontiers in Genetics*, **2019**, 10, 424	4.5	7
49	Iron metabolism and its contribution to cancer (Review). *International Journal of Oncology*, **2019**, 54, 1143-1154	4.4	33
48	Neuroprotective Effect of Echinacoside in Subacute Mouse Model of Parkinson's Disease. *BioMed Research International*, **2019**, 2019, 4379639	3	17
47	Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy. *Blood*, **2019**, 134, 5590-5590	2.2	1
46	BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma. *American Journal of Translational Research (discontinued)*, **2019**, 11, 4139-4150	3	4
45	RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma. *Blood*, **2019**, 134, 3068-3068	2.2	
44	The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma. *Blood*, **2019**, 134, 5586-5586	2.2	
43	Coexistence Of A Huge Venous Thromboembolism And Bleeding Tendency In Cytokine Release Syndrome During CAR-T Therapy. *OncoTargets and Therapy*, **2019**, 12, 8955-8960	4.4	5
42	The impact of the bone marrow microenvironment on multiple myeloma (Review). *Oncology Reports*, **2019**, 42, 1272-1282	3.5	14
41	Echinacoside protects against MPTP/MPP-induced neurotoxicity via regulating autophagy pathway mediated by Sirt1. *Metabolic Brain Disease*, **2019**, 34, 203-212	3.9	25
40	□Hederin inhibits interleukin 6-induced epithelial-to-mesenchymal transition associated with disruption of JAK2/STAT3 signaling in colon cancer cells. *Biomedicine and Pharmacotherapy*, **2018**, 101, 107-114	7.5	25
39	Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. *Blood Cancer Journal*, **2018**, 8, 22	7	13
38	RhPDCD5 combined with dexamethasone increases antitumor activity in multiple myeloma partially via inhibiting the Wnt signalling pathway. *Clinical and Experimental Pharmacology and Physiology*, **2018**, 45, 140-145	3	2
37	Long Non-Coding RNA MEG3 Functions as a Competing Endogenous RNA to Regulate HOXA11 Expression by Sponging miR-181a in Multiple Myeloma. *Cellular Physiology and Biochemistry*, **2018**, 49, 87-100	3.9	28
36	The component formula of Salvia miltiorrhiza and Panax ginseng induces apoptosis and inhibits cell invasion and migration through targeting PTEN in lung cancer cells. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO1-9-4	0	
35	Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. *BMC Cancer*, **2018**, 18, 1152	4.8	9
34	□Hederin Arrests Cell Cycle at G2/M Checkpoint and Promotes Mitochondrial Apoptosis by Blocking Nuclear Factor-□B Signaling in Colon Cancer Cells. *BioMed Research International*, **2018**, 2018, 2548378	3	8
33	4Shydroxywogonin inhibits colorectal cancer angiogenesis by disrupting PI3K/AKT signaling. *Chemico-Biological Interactions*, **2018**, 296, 26-33	5	10

32	OCF can repress tumor metastasis by inhibiting epithelial-mesenchymal transition involved in PTEN/PI3K/AKT pathway in lung cancer cells. *PLoS ONE*, **2017**, 12, e0174021	3.7	9
31	The component formula of and ginseng induces apoptosis and inhibits cell invasion and migration through targeting PTEN in lung cancer cells. *Oncotarget*, **2017**, 8, 101599-101613	3.3	14
30	BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. *Oncotarget*, **2017**, 8, 56858-56867	3.3	4
29	Chromosomal instability and acquired drug resistance in multiple myeloma. *Oncotarget*, **2017**, 8, 78234-78244	3.3	17
28	Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). *Clinical Reviews in Allergy and Immunology*, **2016**, 50, 55-63	12.3	33
27	FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma. *Blood*, **2016**, 128, 4456-4456	2.2	1
26	MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment. *Oncotarget*, **2016**, 7, 4559-69	3.3	13
25	MK2 Is a Therapeutic Target for High-Risk Multiple Myeloma. *Blood*, **2016**, 128, 5612-5612	2.2	
24	Deciphering bacterial community changes in zucker diabetic fatty rats based on 16S rRNA gene sequences analysis. *Oncotarget*, **2016**, 7, 48941-48952	3.3	12
23	BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis. *Medical Oncology*, **2015**, 32, 81	3.7	14
22	NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. *Clinical Cancer Research*, **2015**, 21, 5532-42	12.9	27
21	Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China. *Orphanet Journal of Rare Diseases*, **2015**, 10, 20	4.2	56
20	Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. *Cancer Research*, **2015**, 75, 2211-21	10.1	61
19	Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. *International Journal of Cancer*, **2015**, 136, 1835-44	7.5	52
18	Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. *Cancer Research*, **2015**, 75, 594-604	10.1	57
17	Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy. *Biomaterials Science*, **2014**, 2, 961-971	7.4	31
16	A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling. *Hematological Oncology*, **2014**, 32, 215-7	1.3	1
15	Nek2 is a novel regulator of B cell development and immunological response. *BioMed Research International*, **2014**, 2014, 621082	3	12

14	Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. *Bone*, **2014**, 61, 39-43	4.7	10
13	NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. *Oncotarget*, **2014**, 5, 11986-97	3.3	44
12	Hypermethylation of TAp73 Suppresses ABL1-Involved DNA Damage Response in Multiple Myeloma. *Blood*, **2014**, 124, 3374-3374	2.2	
11	Decreased FPN1 in Myeloma Promotes Malignant Cell Growth and Osteoclast Differentiation. *Blood*, **2014**, 124, 2017-2017	2.2	
10	A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. *Cancer Cell*, **2013**, 23, 502-15	24.3	49
9	NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. *Cancer Cell*, **2013**, 23, 48-62	24.3	178
8	RARα expression confers myeloma stem cell features. *Blood*, **2013**, 122, 1437-47	2.2	53
7	Elevated Expression Of CKS1B Inhibits Senescence Thorough Enhanced Degradation Of p21 In Multiple Myeloma. *Blood*, **2013**, 122, 1882-1882	2.2	2
6	Targeting BTK As a Treatment For Multiple Myeloma Stem Cells. *Blood*, **2013**, 122, 271-271	2.2	1
5	Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies. *Blood*, **2012**, 120, 4073-4073	2.2	1
4	Inhibition of RARα or Its Downstream Signaling Pathways Decreases Drug Resistance in Myeloma. *Blood*, **2011**, 118, 989-989	2.2	
3	The Effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells. *Blood*, **2011**, 118, 2914-2914	2.2	
2	Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. *Oncotarget*, **2010**, 1, 22-33	3.3	83
1	Targeting Myeloma Stem Cells through Simultaneous Inhibition of Wnt and Hedgehog (Hh) Signaling Pathways. *Blood*, **2010**, 116, 615-615	2.2	